News Center
-
Asian Financial Forum | Theresa Tse: Driving Innovative Achievements with International Potential to the Global Stage
From January 26 to 27, the 19th Asian Financial Forum was held in Hong Kong.View -
Eric Tse Attended Winter Davos Forum and Called for Mutual Trust and Recognition to Break Bottlenecks in Biopharmaceutical Globalization
View -
JPM 2026 | Sino Biopharm Leads in siRNA and Tumor Innovation Platforms, M&A Integration Unleashes Long-Term Growth Momentum
On January 15, local time, Sino Biopharm (1177.HK) attended the 44th J.P. Morgan Healthcare Conference and gave a systematic presentation on the company's strategic M&A, technology platforms, and innovative pipeline, showcasing its steady pace of accelerating innovation and expansion to the global market.View -
.jpg)
Major News! Sino Biopharm Acquires Hygieia for RMB 1.2 Billion, Joins Forces with "Industry Dark Horse" in Small Nucleic Acid to Accelerate Layout in Major Chronic Diseases
On January 13, Sino Biopharm (1177.HK) announced that it will fully acquire Hangzhou Hygieia Pharmaceuticals Co., Ltd. (hereinafter referred to as "Hygieia"), a domestic innovative drug company in the small interfering RNA (siRNA) field, for a total price of RMB 1.2 billion.View
Science for a healthier world
